Xeltis secures $55.1M to support aXess commercialization
Summary
The conduit aims to deliver an improved dialysis patient experience while avoiding reinterventions and complications like infections.The device utilizes a proprietary endogenous tissue restoration (ETR) platform. Xeltis designed it to be highly infection-resistant, plus it can deliver near-immediate cannulation.More about the use of proceeds for XeltisXeltis said the funds, in addition to supporting aXess, will be used for its broader pipeline of implants. The aXess EU pivotal trial evaluated adult patients with end-stage renal disease requiring vascular access to start or maintain hemodialysis therapy. The EU pivotal trial for aXess has delivered exceptional data, and with this new financing, we now have both the validation and resources to move forward toward commercialization. We are now looking to expand our production facilities and hire the critical staff that we will need to bring aXess to the market and transform vascular access treatment for hemodialysis patients.